FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      
           
This page is updated frequently with new Cholesterol-related patents. Subscribe to the Cholesterol RSS feed to automatically get the update: related Cholesterol RSS feeds.

Subscribe to updates on this page: Cholesterol RSS RSS

Date/App# patent app List of recent Cholesterol-related patents
04/17/14
20140107196
 Anti-cancer lead molecule patent thumbnailnew patent Anti-cancer lead molecule
Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘a’ (acetyl plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model.
04/17/14
20140107067
 Compositions comprising dietary fat complexers and methods for their use patent thumbnailnew patent Compositions comprising dietary fat complexers and methods for their use
This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without α-cyclodextrin.
04/17/14
20140107029
 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content patent thumbnailnew patent Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of hdl without substantially affecting ldl. These derivatives of hdl are particles with reduced lipid content, particularly reduced cholesterol content.
04/17/14
20140105879
 Flour-based functional food patent thumbnailnew patent Flour-based functional food
The invention relates to a functional flour-based food composition, in particular baked products, and a method for the preparation thereof. Specific substances of vegetable origin principally containing policosanols, isoflavones and vegetable statins are added to the flour, or to the dough for preparing the aforesaid baked products.
04/10/14
20140100275
 Methods of administering compositions comprising docosapentaenoic acid patent thumbnailMethods of administering compositions comprising docosapentaenoic acid
The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (ldl) cholesterol, non-hdl cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.. .
04/10/14
20140100274
 Methods of administering compositions comprising docosapentaenoic acid patent thumbnailMethods of administering compositions comprising docosapentaenoic acid
The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (ldl) cholesterol, non-hdl cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.. .
04/10/14
20140100273
 Methods of administering compositions comprising docosapentaenoic acid patent thumbnailMethods of administering compositions comprising docosapentaenoic acid
The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (ldl) cholesterol, non-hdl cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.. .
04/10/14
20140100272
 Methods of administering compositions comprising docosapentaenoic acid patent thumbnailMethods of administering compositions comprising docosapentaenoic acid
The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (ldl) cholesterol, non-hdl cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.. .
04/10/14
20140099392
 Phaleria macrocarpa extract, extraction process and its use as cholesteryl ester transferase protein (cetp) inhibitor patent thumbnailPhaleria macrocarpa extract, extraction process and its use as cholesteryl ester transferase protein (cetp) inhibitor
An extract and/or herbal fraction and pharmaceutical preparation include extract of phaleria macrocarpa which for the purpose of this invention, is referred to as dlbs1449. The herbal extract according to the teaching of this invention is effectively applicable to inhibit the expression and activity of cholesteryl ester transferase protein (cetp), increase hdl cholesterol level, decrease ldl cholesterol level without raising blood pressure therefore it is further applicable in atherosclerosis therapy..
04/10/14
20140099385
 Inhibition of fatty acid and cholesterol uptake by carbon monoxide (co) patent thumbnailInhibition of fatty acid and cholesterol uptake by carbon monoxide (co)
An object of the present invention is to provide a composition for inhibiting fatty acid and cholesterol uptake in a living cell which is an inhibitor for fatty acid or cholesterol uptake by a living cell, comprising carbon monoxide (co) or a compound capable of releasing co in vivo.. .
04/10/14
20140099312
Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
The present invention provides methods for treating hypercholesterolemia and reducing ldl-c. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-pcsk9 antibody or antigen-binding fragment thereof..
04/03/14
20140094405
Cholesterol derivatives of inhibitors of viral fusion
The present invention relates to compounds comprising at least ten contiguous amino acids of the hr2 domain of a type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the c-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus..
04/03/14
20140093564
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
The present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a dipeptidyl peptidase-4 inhibitor (dpp-4 inhibitor), or a pharmaceutically acceptable salt thereof, and simvastatin, or pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating type 2 diabetes and hypercholesterolemia with such pharmaceutical compositions. In particular, the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and simvastatin..
04/03/14
20140093513
Methods of lowering proprotein conversate subtilisin/kexin type 9 (pcsk9)
The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (pcsk9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases..
03/27/14
20140088073
Methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption
The invention generally relates to methods for determining whether a patient should be administered a drug that inhibits cholesterol absorption. In certain aspects, methods of the invention involve obtaining a sample from a patient, conducting an assay on the sample to obtain a level of a cholesterol absorption marker, and comparing the level to a reference level, in which a level above the reference level indicates that the patient should be administered a drug that inhibits cholesterol absorption..
03/27/14
20140088060
Method of treating disorder related to high cholesteral concentration
Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver x alpha is indicated, such as in, for example, treating a high cholesterol disease.. .
03/27/14
20140088030
Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives
The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (ec 2.4.1.5).
03/27/14
20140087397
Biomarkers for fanconi anemia
A method for adjusting therapy given to a patient having cancer by diagnosing fanconi anemia (fa), and/or predicting bone marrow failure (bmf) or predicting cancer susceptibility in the patient by determining a level of at least one biomarker. In one embodiment the biomarker is at least one of 3-hydroxyisovalerate, acetate, isopropanol, glycerol-3-phosphocholine, choline, histamine, glutamate, alanine, glycine, isoleucine, lysine, phenylalanine, threonine, tyrosine, vitamin a, vitamin d, cholesterol, ketone bodies, acetone, and/or acetoacetate/acetoacetaldehyde.
03/27/14
20140087019
Ready to eat seafood sausages and seafood balls
A ready to eat seafood sausages and seafood balls comestible includes ingredients combined in proportions substantially including: seafood; casing; and seasoning(s). The seafood is cooked to make the seafood sausage.
03/20/14
20140080889
Statin and omega-3 fatty acids for lipid therapy
A method and composition for lipid therapy. In some embodiments, the method comprises providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (ldl-c) level goal, and reducing the triglyceride level and the non-high-density lipoprotein cholesterol (non-hdl-c) level of the subject group as compared to treatment with a 3-hydroxy-3-methyl glutaryl coenzyme a (hmg coa) inhibitor alone, by administering to the subject group an effective amount of an hmg coa inhibitor and a composition comprising omega-3 fatty acids..
03/20/14
20140079785
Composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
A pharmaceutical composition comprises, as a therapeutically active ingredient, a corticosteroid and/or vitamin d derivative incorporated as a solid solution or dispersion in lipid nanoparticles, said lipid nanoparticles being solid at ambient temperature and comprising a first lipid with a melting point above body temperature, the first lipid being a wax selected from the group consisting of esters of c12-24 alcohols and c12-24 fatty acids, glyceryl mono-, di- or triesters of c12-24 fatty acids, c12-24 fatty alcohols, and cholesterol, optionally a second lipid which is an oil at ambient temperature and miscible with the first lipid, and a pharmaceutically acceptable surfactant.. .
03/20/14
20140079729
Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit
Shilajit in a standardized composition produces a significant improvement in several cardiovascular parameters including ri, aix and sevr. Further, significant reductions in malondialdehyde and increases in nitric oxide levels are provided suggesting improvement in endothelial function.
03/13/14
20140073703
Phytol as a cholesterol lowering agent
Phytol (3,7,11,15-tetramethyl-2-hexadecen-1-ol),orderivates thereof, of natural or synthetic origin are used as active ingredient in formulations to lower serum levels of triglycerides and/or cholesterol. Phytol can be administered to patients with disease conditions related to increased levels of cholesterol or triglycerides such as type ii diabetes, obesity or other patients in risk of cardiovascular diseases due to elevated cholesterol levels.
03/13/14
20140073652
Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
Provided herein are methods and compounds for post-translational regulation of cytochrome p450 46a1 (cyp46a1) enzyme activity in the brain and retina. Also, a method for identifying a potential regulator of a cyp46a1 enzyme using crystal structures of the enzyme and a subsequent method for screening for a regulatory activity in the presence of cyp46a1 enzyme are provided.
03/13/14
20140072580
Novel targets for treatment of hypercholesterolemia
In certain embodiments this invention this invention pertains to the discovery that inhibition of myosin light chain interacting protein (mylip) can mitigate one or more symptoms of hypercholesterolemia. Methods of treating hypercholesterolemia and methods of screening for agents to treat hypercholesterolemia are provided..
03/13/14
20140072544
Polybacterial preparation with health benefits: antioxidant effect, reduction of cholesterol concentration, anti-inflammatory immunomodulating effect and release of bioactive peptides inhibiting angiotensin-converting enzyme
This invention relates to polybacterial probiotic preparation, which includes new strains of lactic acid bacteria lactobacillus gasseri 7/12 nbimcc no. 8720, lactobacillus plantarum f12 nbimcc no 8722 and lactobacillus helveticus a1, nbimcc no 8721 and has the following set of properties: antioxidant, hypocholesterolemic effect, anti-inflammatory immunomodulating effect, ability to release bioactive peptides that inhibit angiotensin-converting enzyme (ace), which is responsible for the high blood pressure.
02/27/14
20140058125
Ortho-fluoro substituted compounds for the treatment of metabolic diseases
There is provided novel fluoro-substituted compounds capable of modulating the g-protein-coupled receptor gpr40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type ii diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.. .
02/27/14
20140057846
Products and methods using soy peptides to lower total and ldl cholesterol levels
Controlled studies demonstrate that products and related methods using soy related peptides lower total and ldl cholesterol levels in individuals. In one exemplary embodiment of the present disclosure, a product containing an effective amount of lunasin peptides that lowers cholesterol levels in an individual that consumes the lunasin peptides is provided.
02/27/14
20140057038
Process of obtaining a chia based energy drink
Process of obtaining a chia based energy drink able to combine the stimulating properties of compounds such as taurine, caffeine and inositol with the anti-oxidizing benefits of the chia seed, retrieving a traditional beverage, “cool chia” in the form of an industrialized product, allowing for the effective use of the combination of raw materials used for the composition of the beverage benefiting health, in terms of neurologic functions, as it is a stimulant, as well as in terms of weight control, as it is an antioxidant and a low-calorie energy source for the body, controlling cholesterol and triglycerides and regulating the intestine.. .
02/27/14
20140057021
Composition for a chia based energy drink
Composition for an energy drink based on chia seed able to combine the stimulating properties of compounds such as taurine, caffeine and inositol with the anti-oxidizing benefits of the chia seed, retrieving a traditional beverage, “cool chia” in the form of an industrialized product, allowing for the effective use of the combination of raw materials used for the composition of the beverage benefiting health, in terms of neurologic functions, as it is a stimulant, as well as in terms of weight control, as it is an antioxidant and a low-calorie energy source for the body, controlling cholesterol and triglycerides and regulating the intestine.. .
02/20/14
20140051746
Methods targeting mir-128 for regulating cholesterol/lipid metabolism
Methods for targeting microrna 128 (mir-128) for regulating cholesterol/lipid metabolism and insulin sensitivity.. .
02/20/14
20140050810
Anti-obesity composition comprising lycium chinensis leaf extract and betaine as active ingredient
Disclosed are betaine and a lycium chinensis leaf extract and a mixture thereof which are preventive and therapeutic of obesity, and uses thereof. They are found to have prophylactic and therapeutic effects on obesity and obesity-induced metabolic syndrome as evaluated for reductive activity against weight, body fat, total cholesterol, triglyceride, and ldl in humans and in mice.
02/20/14
20140050800
Method of reducing oxidative stress
Methods of ameliorating cellular oxidative stress and reducing serum cholesterol are disclosed.. .
02/20/14
20140049775
Measurement of serum lipoproteins
Although a more accurate estimate of a person's risk of cardiovascular disease can be made on the basis of the number of lipoprotein particles per unit volume in the person's blood, current methods all rely on measuring the mass of lipoprotein cholesterol per unit volume. It has been discovered that a rapid and accurate lipoprotein particle count can be obtained by photometry.
02/13/14
20140045746
Antidiabetic tricyclic compounds
Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
02/13/14
20140045201
Method for quantifying cholesterol in high-density lipoprotein 2, and reagent kit for the method
Disclosed is a method for quantifying hdl2 cholesterol in a test sample without requiring laborious operations. The method for quantifying cholesterol comprises allowing phospholipase to act on hdl to quantify cholesterol.
02/13/14
20140044784
Combined formulation with improved stability
Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability..
02/13/14
20140044757
Method for selectively inhibiting acat1 in the treatment of alzheimer's disease
The present invention features methods for stimulating clearance of amyloid beta in microglia, decreasing cognitive decline associated with amyloid pathology, and treating alzheimer's disease by selectively inhibiting the expression or activity of acyl-coa:cholesterol acyltransferase 1, but not acyl-coa:cholesterol acyltransferase 2.. .
02/13/14
20140044730
Anti-pcsk9 antibodies with ph-dependent binding characteristics
The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (pcsk9) with greater affinity at neutral ph than at acidic ph. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit ph-dependent binding properties.
02/06/14
20140039163
Cholesterol-dependent cytolysin variant and use thereof in dds
The present invention provides a carrier capable of delivering a medical agent capsule encapsulating a medical agent to various target cells and tissues to cause the medical agent to be taken therein in an efficient and highly safe manner, and a drug delivery system using the carrier. The carrier has a cell or tissue specific antibody bound to an antibody binding domain of a cholesterol-dependent cytolysin variant of the present invention.
02/06/14
20140038953
Compositions and methods for cardiovascular disease
The present invention provides small molecule inhibitors of bmp signaling. These compounds may be used to reduce circulating levels of apob-100 or ldl.
01/30/14
20140031335
Cycloalkenyl aryl derivatives for cetp inhibitor
The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of cetp activity inhibition.
01/30/14
20140031304
Anti-cholesterolemic compounds and methods of use
The present invention provides novel compounds with hypocholesteremic activity from crude embilica officinialis (eo) extracts and methods of use. The invention also provides nutraceuticals..
01/30/14
20140030270
Methods of treating or preventing cholesterol related disorders
The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (pcsk9). Formulations and methods of producing said formulations are also described..
01/23/14
20140024632
Methods for treatment of autism spectrum disorder
The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorder.
01/23/14
20140024613
Methods for treating hcv
In one aspect, the present invention features hcv therapies comprising administering to a patient in need thereof an hcv protease inhibitor and ritonavir, wherein ritonavir is used as a pharmacokinetic booster to improve the pharmacokinetics of the hcv protease inhibitor. The hcv therapies do not require the testing of total cholesterol and triglyceride levels prior to and after the therapies..
01/23/14
20140024061
Detection of lcat activity
The present disclosure relates to methods for detecting and measuring the activity of lecithin:cholesterol acyltransferase (lcat) in solution (e.g. Serum, plasma, cell culture media, aqueous solution) with fluorescent sterol substrates.
01/23/14
20140023631
Methods of treating anemia and red blood cell dysfunction with lecithin cholesterol acyltransferase
Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous lcat or lcat activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells..
01/16/14
20140018546
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
Novel forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, form xxv, form xxvi, form xxvii, form xxviii, form xxix, and form xxx, characterized by their x-ray powder diffraction, solid-state nmr, and/or raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer's disease.. .
01/16/14
20140018426
Food or beverage composition fortified with thyronamines and/or thyronamine precursors
Food or beverage compositions fortified with thyronines and/or thyronamines, processes for increasing t2, t1am, and/or t0am in a subject by administering a food or beverage composition that is fortified with at least one thyronine and/or thyronamine compound, and processes for promoting a healthy state by administering a food or beverage composition to a subject that is fortified with at least one thyronine and/or thyronamine compound. Increased levels of t2, t1am, and/or t0am in a subject can be associated with at least one of healthy cholesterol levels, healthy triglyceride levels, healthy blood sugar levels, cardiovascular health, healthy sleep patterns, healthy mood, healthy skin, healthy nails, or healthy endocrine function and/or a number of other markers of associated with general health and well-being..
01/16/14
20140018332
Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid
Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin d analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(s)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(s)-2-methylene-1α,25-dihydroxyvitamin d3, 2-methylene-1α,25-dihydroxy-(17e)-17(20)-dehydro-19-nor-vitamin d3, 2-methylene-19-nor-(24r)-1α,25-dihydroxyvitamin d2, 2-methylene-(20r,25s)-19,26-dinor-1α,25-dihydroxyvitamin d3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20r)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20s)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20s)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol, (2-(3′ hydroxypropyl-1′,2′-idene)-19,23,24-trinor-(20s)-1α-hydroxyvitamin d3, 2-methylene-18,19-dinor-(20s)-1α,25-dihydroxyvitamin d3, a stereoisomer thereof, a prodrug thereof in oral compositions, a salt thereof, and/or a solute thereof.
01/16/14
20140017312
Multi-vitamin and mineral nutritional supplements
The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (ldl-c) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol.
01/09/14
20140010885
Self-assembling nanoparticle drug delivery system
A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as hepatitis b virus core protein, encapsulating the bioactive agent, a lipid layer or lipid/cholesterol layer coat and targeting or facilitating molecules anchored in the lipid layer.
01/09/14
20140010848
Gas-filled microbubbles and systems for gas delivery
Compressible and concentrated suspensions containing gas-filled microbubbles, uses thereof for delivering gas into a subject in need thereof, and systems for delivering the compressible suspensions. The gas-filled microbubbles each comprise a gas core surrounded by a lipid membrane, which includes (a) one or more lipids, such as 1,2-disteroyl-sn-glycero-3-phosphocholine (dspc) or dipalmitoylphosphatidylcholine (dppc), and (b) one or more stabilizing detergents, such as poloxamer 188, pluronic f108, pluronic f127, polyoxyethylene (100) stearyl ether, cholesterol, gelatin, polyvinylpyrrolidone (pvp), and sodium deoxycholate (nadoc)..
01/02/14
20140005384
Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
Novel salt forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid characterized by their x-ray powder diffraction pattern and solid-state nmr spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and alzheimer's disease.. .
01/02/14
20140005187
Oxidosqualene cyclase as a protein target for anticancer therapeutics
The present invention identifies the cholesterol biosynthetic pathway, including the enzyme oxidosqualene cyclase, as new protein targets for anti-tumor therapeutics. The present invention further provides a class of oxidosqualene cyclase inhibitors containing a tertiary amine linked with aromatic ring structures, as a new class of anticancer agents.
01/02/14
20140004459
Toner for developing electrostatic charge image
The present invention is a toner for developing electrostatic charge image containing a wax derived from a plant cholesterol, an electric charge-controlling agent, a coloring agent and a binding resin. The toner is suited for use in the electromagnetic induction-heated fixing system which is capable of heating the heating member up to a predetermined fixing temperature in a short period of time, makes it possible to maintain images free of irregular luster or fouling for extended periods of time and is, further, suited for being fixed at a low temperature..
01/02/14
20140004122
Methods for treating or preventing cholesterol related disorders
The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (pcsk9). Formulations and methods of producing said formulations are also described..
12/26/13
20130345188
Preparation and uses of obeticholic acid
Or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a fxr mediated disease or condition, cardiovascular disease or cholestatic liver disease, and for reducing hdl cholesterol, for lowering triglycerides in a mammal, or for inhibition of fibrosis.
12/26/13
20130345187
Method for pre-screening and correlation of underlying scarb1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment
A method of genotyping women experiencing infertility for non-physical reasons in order to identify the presence of the rs4238001 and/or rs10846744 mutation of the scarb1 gene and, upon identifying the presence of one or both genetic mutations, administering a tailored therapeutic regimen to restore fertility by either one or a combination of 1) mediating the flux of cholesterol resulting from the mutation by therapeutic use of the cholesterol medication probucol and/or other cholesterol altering medications, and/or 2) amplifying the presence of hormone progesterone by therapeutic use of progestational and progestin medications.. .
12/26/13
20130345182
Stable composition comprising cholesterol-lowering agents, antihypertensive agents and antiplatlet agents
The present invention relates to a stable composition for providing substances with different types of activity, such as cholesterol lowering agents, antihypertensive agents and antiplatelet agents, which substantially reduce the dosage required to prevent cardiovascular events.. .
12/26/13
20130345116
Composition containing trail for prevention or treatment of metabolic diseases
The present invention provides a pharmaceutical composition and a food composition containing tumor necrosis factor (tnf)-related apoptosis-inducing ligand (trail) as an active ingredient for prevention or treatment of metabolic diseases. The trail according to the present invention can reduce blood glucose, neutral fat, cholesterol, and free fatty acid, and neutral fat in liver, and reduce the synthesis of fat, and promote the lipid metabolism, and thus can be effectively used for the prevention or treatment of metabolic diseases..


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2981

3635

2 - 1 - 74